Class I antiarrhythmic drugs like cibenzoline can have dangerous proarrhythmic effects during exercise in patients with hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Cibenzoline warrants caution in HCM patients; this case leaves open Na-channel blocker safety in arrhythmogenic substrates.
We report a 17-year-old woman with hypertrophic cardiomyopathy (HCM) successfully resuscitated from ventricular fibrillation while taking cibenzoline. During exercise-stress testing before implanting an implantable cardioverter-defibrillator, ventricular tachycardia was induced and thought to be a proarrhythmia due to the use-dependent effect of the Na channel blockade with cibenzoline. In patients with arrhythmogenic substrates such as HCM, it is critical to pay attention to the proarrhythmic effects of class I antiarrhythmic drugs while increasing heart rate.
No takes yet. Share an insight, caveat, or question.
Shiohira et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: